Fibrocell Science Company Profile (NASDAQ:FCSC)

About Fibrocell Science (NASDAQ:FCSC)

Fibrocell Science logoFibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:FCSC
  • CUSIP: N/A
  • Web: www.fibrocell.com
Capitalization:
  • Market Cap: $54.01 million
  • Outstanding Shares: 14,717,000
Average Prices:
  • 50 Day Moving Avg: $2.94
  • 200 Day Moving Avg: $2.67
  • 52 Week Range: $1.57 - $4.64
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.04
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $252,000.00
  • Price / Sales: 200.90
  • Book Value: ($0.75) per share
  • Price / Book: -4.59
Profitability:
  • EBIDTA: ($18,040,000.00)
  • Net Margins: -4,307.60%
  • Return on Equity: -293.07%
  • Return on Assets: -91.03%
Debt:
  • Current Ratio: 4.78%
  • Quick Ratio: 4.78%
Misc:
  • Average Volume: 79,250 shs.
  • Beta: 0.31
  • Short Ratio: 3.46
 

Frequently Asked Questions for Fibrocell Science (NASDAQ:FCSC)

What is Fibrocell Science's stock symbol?

Fibrocell Science trades on the NASDAQ under the ticker symbol "FCSC."

How were Fibrocell Science's earnings last quarter?

Fibrocell Science Inc (NASDAQ:FCSC) announced its earnings results on Wednesday, August, 9th. The company reported ($0.31) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.31). Fibrocell Science had a negative return on equity of 293.07% and a negative net margin of 4,307.60%. View Fibrocell Science's Earnings History.

When will Fibrocell Science make its next earnings announcement?

Fibrocell Science is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for Fibrocell Science.

Where is Fibrocell Science's stock going? Where will Fibrocell Science's stock price be in 2017?

3 equities research analysts have issued 1-year price objectives for Fibrocell Science's stock. Their forecasts range from $2.00 to $7.00. On average, they anticipate Fibrocell Science's stock price to reach $4.90 in the next twelve months. View Analyst Ratings for Fibrocell Science.

Who are some of Fibrocell Science's key competitors?

Who are Fibrocell Science's key executives?

Fibrocell Science's management team includes the folowing people:

  • Douglas J. Swirsky, Chairman of the Board
  • John M. Maslowski, President, Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer
  • Lisa A. Embon, Vice President - of Corporate Accounting , Controller
  • Kelvin Moore, Lead Independent Director
  • Julian P. Kirk, Director
  • Marcus E. Smith, Director
  • Marc B. Mazur, Independent Director
  • Christine Thompson St.Clare, Independent Director

Who owns Fibrocell Science stock?

Fibrocell Science's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Third Security LLC (37.70%), FMR LLC (5.79%), Vanguard Group Inc. (2.36%), Cambridge Investment Research Advisors Inc. (0.46%), Creative Planning (0.42%) and Parametric Portfolio Associates LLC (0.33%). View Institutional Ownership Trends for Fibrocell Science.

Who sold Fibrocell Science stock? Who is selling Fibrocell Science stock?

Fibrocell Science's stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc. and FMR LLC. View Insider Buying and Selling for Fibrocell Science.

Who bought Fibrocell Science stock? Who is buying Fibrocell Science stock?

Fibrocell Science's stock was bought by a variety of institutional investors in the last quarter, including Creative Planning, Parametric Portfolio Associates LLC and Bank of New York Mellon Corp. View Insider Buying and Selling for Fibrocell Science.

How do I buy Fibrocell Science stock?

Shares of Fibrocell Science can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Fibrocell Science's stock price today?

One share of Fibrocell Science stock can currently be purchased for approximately $3.44.


MarketBeat Community Rating for Fibrocell Science (NASDAQ FCSC)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  108 (Vote Outperform)
Underperform Votes:  80 (Vote Underperform)
Total Votes:  188
MarketBeat's community ratings are surveys of what our community members think about Fibrocell Science and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Fibrocell Science (NASDAQ:FCSC) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $4.90 (42.44% upside)

Analysts' Ratings History for Fibrocell Science (NASDAQ:FCSC)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/15/2017HC WainwrightReiterated RatingBuy$5.70HighView Rating Details
9/11/2017Canaccord GenuityReiterated RatingBuy$3.00 -> $7.00LowView Rating Details
3/7/2017Rodman & RenshawInitiated CoverageBuy -> Buy$2.00N/AView Rating Details
7/6/2016Griffin SecuritiesReiterated RatingBuy$12.00N/AView Rating Details
6/8/2016Roth CapitalReiterated RatingBuy$5.00N/AView Rating Details
6/8/2016WedbushReiterated RatingNeutral$1.50 -> $4.00N/AView Rating Details
(Data available from 9/23/2015 forward)

Earnings

Earnings History for Fibrocell Science (NASDAQ:FCSC)
Earnings by Quarter for Fibrocell Science (NASDAQ:FCSC)
Earnings History by Quarter for Fibrocell Science (NASDAQ FCSC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017        
8/9/2017Q2 2017($0.31)($0.31)ViewListenView Earnings Details
5/10/2017Q1 2017($0.29)($0.58)ViewN/AView Earnings Details
11/3/2016Q316($0.15)($0.05)$0.07 million$0.22 millionViewN/AView Earnings Details
3/10/2016Q415($0.17)($0.40)$0.07 million$0.08 millionViewListenView Earnings Details
11/5/2015Q315($0.16)($0.07)$0.06 million$0.08 millionViewN/AView Earnings Details
8/6/2015Q215($0.16)($0.17)$0.09 million$0.14 millionViewN/AView Earnings Details
5/8/2015Q1 2015($0.16)($0.17)$0.05 million$0.19 millionViewN/AView Earnings Details
3/13/2015Q4 2014($0.16)($0.16)$0.06 million$0.06 millionViewN/AView Earnings Details
11/7/2014Q3 14($0.14)($0.17)$0.06 million$0.02 millionViewN/AView Earnings Details
8/11/2014Q2 2014($0.18)($0.08)$0.07 million$0.06 millionViewN/AView Earnings Details
5/19/2014Q114($0.15)($0.35)$0.05 million$0.05 millionViewN/AView Earnings Details
3/17/2014Q414($0.26)($0.14)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Fibrocell Science (NASDAQ:FCSC)
2017 EPS Consensus Estimate: ($0.77)
2018 EPS Consensus Estimate: ($1.01)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($0.31)($0.07)($0.19)
Q2 20174($0.34)($0.07)($0.20)
Q3 20174($0.35)($0.05)($0.20)
Q4 20173($0.37)($0.05)($0.20)
Q1 20181($0.26)($0.26)($0.26)
Q2 20181($0.29)($0.29)($0.29)
Q3 20181($0.23)($0.23)($0.23)
Q4 20181($0.23)($0.23)($0.23)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Fibrocell Science (NASDAQ:FCSC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Fibrocell Science (NASDAQ:FCSC)
Insider Ownership Percentage: 2.10%
Institutional Ownership Percentage: 54.70%
Insider Trades by Quarter for Fibrocell Science (NASDAQ:FCSC)
Institutional Ownership by Quarter for Fibrocell Science (NASDAQ:FCSC)
Insider Trades by Quarter for Fibrocell Science (NASDAQ:FCSC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/2/2016David PernockChairmanBuy50,000$0.92$46,000.00View SEC Filing  
11/13/2015David PernockCEOBuy3,000$5.00$15,000.00View SEC Filing  
8/11/2015David PernockCEOBuy3,500$6.54$22,890.00View SEC Filing  
7/27/2015Randal J KirkMajor ShareholderBuy975,987$5.80$5,660,724.60View SEC Filing  
5/13/2015David PernockCEOBuy16,600$4.30$71,380.00View SEC Filing  
12/12/2014David PernockCEOBuy5,000$2.52$12,600.00View SEC Filing  
11/20/2014David PernockCEOBuy5,000$2.54$12,700.00View SEC Filing  
11/20/2014John Michael MaslowskiVPBuy1,000$2.54$2,540.00View SEC Filing  
6/5/2014Christine St.ClareDirectorBuy10,000$3.00$30,000.00View SEC Filing  
6/5/2014David PernockCEOBuy12,500$2.95$36,875.00View SEC Filing  
6/4/2014Kelvin MooreDirectorBuy4,557$2.99$13,625.43View SEC Filing  
6/4/2014Randal J KirkMajor ShareholderBuy400,000$2.90$1,160,000.00View SEC Filing  
1/24/2014Randal J KirkMajor ShareholderBuy1,024,590$4.88$4,999,999.20View SEC Filing  
11/21/2013David PernockCEOBuy10,000$3.69$36,900.00View SEC Filing  
11/20/2013Gregory L WeaverCFOBuy10,000$3.51$35,100.00View SEC Filing  
10/1/2013Randal J KirkMajor ShareholderBuy3,658,536$4.10$14,999,997.60View SEC Filing  
7/26/2013Randal J KirkMajor ShareholderBuy1,243,781$6.03$7,499,999.43View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Fibrocell Science (NASDAQ:FCSC)
Latest Headlines for Fibrocell Science (NASDAQ:FCSC)
Source:
DateHeadline
americanbankingnews.com logoFibrocell Science Inc (FCSC) Upgraded at Zacks Investment Research
www.americanbankingnews.com - September 22 at 11:00 PM
americanbankingnews.com logoFibrocell Science Inc (FCSC) Stock Rating Reaffirmed by Canaccord Genuity
www.americanbankingnews.com - September 17 at 10:22 PM
americanbankingnews.com logo Analysts Expect Fibrocell Science Inc (FCSC) to Post -$0.41 Earnings Per Share
www.americanbankingnews.com - September 16 at 12:08 AM
americanbankingnews.com logoFibrocell Science Inc (FCSC) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - September 15 at 10:32 PM
americanbankingnews.com logoFibrocell Science Inc (FCSC) Coverage Initiated by Analysts at HC Wainwright
www.americanbankingnews.com - September 15 at 7:28 AM
seekingalpha.com logoFibrocell Science (FCSC) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 11 at 7:09 PM
benzinga.com logo10 Biggest Mid-Day Gainers For Friday - Benzinga
www.benzinga.com - September 8 at 7:03 PM
finance.yahoo.com logoFibrocell to Present at Rodman & Renshaw 19th Annual Global Investment Conference and Global Genes’ 2017 RARE Patient Advocacy Summit
finance.yahoo.com - September 5 at 8:14 PM
americanbankingnews.com logoZacks: Analysts Anticipate Fibrocell Science Inc (FCSC) Will Announce Earnings of -$0.41 Per Share
www.americanbankingnews.com - August 28 at 12:22 PM
americanbankingnews.com logoBrokers Offer Predictions for Fibrocell Science Inc's Q1 2018 Earnings (FCSC)
www.americanbankingnews.com - August 14 at 6:58 AM
americanbankingnews.com logoFibrocell Science Inc (NASDAQ:FCSC) Posts Quarterly Earnings Results, Meets Expectations
www.americanbankingnews.com - August 11 at 2:06 PM
americanbankingnews.com logo Analysts Anticipate Fibrocell Science Inc (NASDAQ:FCSC) to Post -$0.31 EPS
www.americanbankingnews.com - August 10 at 8:06 AM
finance.yahoo.com logoFibrocell Reports Second Quarter 2017 Financial Results and Recent Highlights
finance.yahoo.com - August 9 at 6:47 PM
finance.yahoo.com logoFibrocell Science reports 2Q loss
finance.yahoo.com - August 9 at 6:46 PM
finance.yahoo.com logoFibrocell to Present at Canaccord Genuity 37th Annual Growth Conference
finance.yahoo.com - August 3 at 3:40 PM
americanbankingnews.com logoFibrocell Science Inc (NASDAQ:FCSC) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - August 3 at 10:58 AM
zacks.com logoWhat's in Store for Intrexon (XON) in this Earnings Season?
www.zacks.com - August 2 at 7:29 PM
finance.yahoo.com logoFibrocell to Host Conference Call and Webcast on Wednesday, August 9, 2017 to Discuss Second Quarter 2017 Financial Results and Recent Operational Highlights
finance.yahoo.com - August 2 at 7:29 PM
finance.yahoo.com logoWhat's in Store for Intrexon (XON) in this Earnings Season?
finance.yahoo.com - August 2 at 7:29 PM
americanbankingnews.com logoFibrocell Science Inc (FCSC) Upgraded by ValuEngine to "Hold"
www.americanbankingnews.com - July 21 at 12:04 AM
americanbankingnews.com logo-$0.31 EPS Expected for Fibrocell Science Inc (NASDAQ:FCSC) This Quarter
www.americanbankingnews.com - July 20 at 10:15 PM
americanbankingnews.com logoFibrocell Science Inc (FCSC) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - July 19 at 11:44 PM
americanbankingnews.com logoFibrocell Science Inc (FCSC) Expected to Announce Earnings of -$0.31 Per Share
www.americanbankingnews.com - June 26 at 6:30 PM
americanbankingnews.com logoFibrocell Science Inc (FCSC) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - June 20 at 10:46 AM
americanbankingnews.com logoFibrocell Science Inc (FCSC) Upgraded by ValuEngine to "Sell"
www.americanbankingnews.com - June 15 at 8:50 PM
americanbankingnews.com logoCritical Analysis: Juniper Pharmaceuticals (JNP) versus Fibrocell Science (FCSC)
www.americanbankingnews.com - June 14 at 12:46 AM
rttnews.com logoXLRN's DART Misses Mark, RGLS Makes Cuts In Pipeline, FDA Snubs CHRS
www.rttnews.com - June 13 at 11:33 AM
streetinsider.com logoFibrocell Science (FCSC) Announces Rare Pediatric Disease Designation from FDA for FCX-013 for Treatment of Localized Scleroderma
www.streetinsider.com - June 13 at 11:33 AM
bizjournals.com logoWhy 2 rare pediatric disease designations could bring big bucks for Exton gene therapy developer
www.bizjournals.com - June 12 at 6:01 PM
finance.yahoo.com logoFibrocell Receives Rare Pediatric Disease Designation from FDA for FCX-013 for Treatment of Localized Scleroderma
finance.yahoo.com - June 12 at 6:01 PM
americanbankingnews.com logoFibrocell Science's (FCSC) "Buy" Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - June 9 at 7:56 AM
streetinsider.com logoFibrocell Science (FCSC) Completes Dosing of First Cohort in Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for RDEB
www.streetinsider.com - June 8 at 6:11 PM
finance.yahoo.com logoFibrocell Completes Dosing of First Cohort in Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Treatment of Recessive Dystrophic Epidermolysis Bullosa
finance.yahoo.com - June 8 at 6:11 PM
americanbankingnews.com logoFibrocell Science Inc (FCSC) Cut to "Strong Sell" at ValuEngine
www.americanbankingnews.com - June 4 at 5:34 PM
americanbankingnews.com logoZacks: Analysts Anticipate Fibrocell Science Inc (FCSC) Will Announce Earnings of -$0.31 Per Share
www.americanbankingnews.com - May 31 at 4:46 PM
americanbankingnews.com logoFibrocell Science Inc (FCSC) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - May 26 at 11:17 AM
americanbankingnews.com logoBrokers Set Expectations for Fibrocell Science Inc's FY2020 Earnings (FCSC)
www.americanbankingnews.com - May 22 at 11:00 AM
seekingalpha.com logoFibrocell Science's (FCSC) CEO John Maslowski on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 12 at 10:44 PM
americanbankingnews.com logoFibrocell Science Inc (FCSC) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 11 at 9:00 PM
zacks.com logoIntrexon (XON) Q1 Loss Wider than Expected, Revenues Beat
www.zacks.com - May 11 at 5:46 PM
finance.yahoo.com logoInvestor Network: Fibrocell Science, Inc. to Host Earnings Call
finance.yahoo.com - May 10 at 10:18 PM
marketbeat.com logoFibrocell Science reports 1Q loss
marketbeat.com - May 10 at 8:33 AM
finance.yahoo.com logoFibrocell and Intrexon Announce Two Oral Presentations at the 20th Annual Meeting of the American Society of Gene & Cell Therapy
finance.yahoo.com - May 9 at 9:27 AM
streetinsider.com logoFibrocell Science (FCSC) Announces DSMB Recommends Continuation of Phase 1/2 Clinical Trial of FCX-007 for Treatment of RDEB
www.streetinsider.com - May 8 at 9:03 AM
americanbankingnews.com logo-$0.29 EPS Expected for Fibrocell Science Inc (FCSC) This Quarter
www.americanbankingnews.com - May 5 at 4:20 PM
finance.yahoo.com logoFibrocell to Host Conference Call and Webcast on Wednesday, May 10, 2017 to Discuss First Quarter 2017 Financial Results and Recent Operational Highlights
finance.yahoo.com - May 3 at 8:17 AM
americanbankingnews.com logoFibrocell Science Inc (FCSC) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 1 at 2:48 PM
americanbankingnews.com logoFibrocell Science (FCSC) Receives News Sentiment Score of 0.33
www.americanbankingnews.com - April 16 at 1:25 PM
americanbankingnews.com logoZacks: Analysts Expect Fibrocell Science Inc (FCSC) Will Post Earnings of -$0.29 Per Share
www.americanbankingnews.com - April 14 at 4:30 PM
americanbankingnews.com logoFibrocell Science (FCSC) Receives Daily Media Impact Rating of 0.09
www.americanbankingnews.com - April 13 at 7:00 PM

Social

Chart

Fibrocell Science (FCSC) Chart for Saturday, September, 23, 2017

This page was last updated on 9/23/2017 by MarketBeat.com Staff